Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 14 of the 32 sources its claims cite were checked for support.
Abstract
BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. RESULTS: ; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively. CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).
Overview
CoChat Summary
## TL;DR
MajesTEC-3 is a phase 3 randomized trial in relapsed/refractory multiple myeloma showing that teclistamab plus daratumumab (Tec-Dara) improved progression-free survival and overall survival versus standard daratumumab-based care. The combination also increased response depth and MRD negativity, but it came with frequent adverse events, including infections and treatment-emergent fatal events.
## Key findings
- 587 patients were randomized (Tec-Dara, n=291; DPd/DVd, n=296); median follow-up was 34.5 months.
- Estimated 36-month progression-free survival was 83.4% with Tec-Dara versus 29.7% with DPd/DVd; HR 0.17 (95% CI, 0.12–0.23; P<0.0001).
- Complete response or better occurred in 81.8% vs. 32.1%, overall response in 89.0% vs. 75.3%, and MRD negativity at 10^-5 in 58.4% vs. 17.1% with Tec-Dara vs. DPd/DVd, all significantly favored Tec-Dara.
- Estimated 36-month overall survival was 83.3% with Tec-Dara and 65.0% with DPd/DVd (P<0.0001); time to worsening of symptoms also favored Tec-Dara (36-month event-free rate 75.6% vs. 63.3%; HR 0.50).
- Safety was substantial in both groups: grade 3/4 adverse events occurred in 95.1% vs. 96.6%, deaths due to treatment-emergent adverse events in 7.1% vs. 5.9%, and grade 3/4 infections in 54.1% vs. 43.4% with Tec-Dara vs. DPd/DVd.
## Methods
- Multicenter, open-label, phase 3 randomized study across 150 sites in 20 countries; patients were randomized 1:1 to Tec-Dara or investigator’s choice of DPd/DVd.
- Eligible patients had 1–3 prior lines of antimyeloma therapy, including a proteasome inhibitor and lenalidomide, with progression on or after the last regimen; key exclusions included prior BCMA-directed therapy and anti-CD38 refractoriness.
- Primary endpoint was progression-free survival by blinded independent review committee; key secondary endpoints included ≥CR, overall response, MRD negativity, overall survival, and symptom worsening; analyses used stratified log-rank tests, Cox models, and hierarchical testing.
## Limitations
- The paper states that the width of confidence intervals was not adjusted for multiplicity and “may not be used in place of hypothesis testing.”
- The paper notes that subgroup findings for prior anti-CD38 exposure, age >75 years, and ECOG performance status 2 were based on “a few patients” or “small” subgroups; this limits certainty in those strata.
- Evident from the text: the study was open-label, which can introduce bias in subjective outcomes such as symptom reporting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
9 Valid · 3 Not valid · 4 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
What the sources say
- Partly supportedcites [36] Raje N, Anderson K, Einsele H, Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 2023; 13: 116. 37528088 PMC10394080 sourceExperimental — accuracy not yet measured
The Consensus recommendations (Risk factors for infection; page not provided) recommend monthly IVIG for patients with immunoparesis receiving bispecific antibodies, and discuss immunoglobulin replacement for patients at particular infection risk. The passages do not identify these as IMWG guidelines or report that early replacement reduces high-grade infections; the claim states that outcome more firmly than this source supports. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [37] Raje NS, Anaissie E, Kumar SK, Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 2022; 9: e143– e61. 35114152 source
- Partly supportedcites [38] Lancman G, Parsa K, Kotlarz K, IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov 2023; 4: 440– 51. 37769148 PMC10618720 sourceExperimental — accuracy not yet measured
Our copy supports the core of the claim: in the self-controlled case series of 37 anti-BCMA bispecific antibody patients, the grade 3-5 infection rate was 90% lower on IVIg (IRR 0.10; 95% CI 0.01-0.80; P=0.0307; Introduction and Discussion), and the authors argue for early/primary prophylaxis rather than the traditional reactive strategy, listing IVIg q4 weeks among their prevention recommendations (Table 3, Discussion). Two attributed elements are not supported: (1) the 'per IMWG guidelines' provenance — IMWG criteria are used in our copy only for disease-response assessment (Definitions, ref 40), while the traditional immunoglobulin-replacement recommendations are credited to other guidelines (refs 24-26: Anderson 2007 IVIG-for-hematologic-conditions guidelines, Terpos 2015 European Myeloma Network, Girmenia 2019 expert panel); (2) the claim states reduction as established fact, whereas the paper hedges it as a retrospective, nonrandomly administered association 'suggesting a role for IVIg as primary prophylaxis' pending randomized confirmation. (LLM, conf=0.78)
- Not matchedcites [39] Balev M, Shah N, Shah MR, Efficacy and safety of teclistamab in relapsed refractory multiple myeloma: long-term follow-up from a real world multi-institutional cohort. Presented at: 66th American Society of Hematology (ASH) Annual Meeting; December 7–10, 2024; San Diego, CA, USA.
We don’t have this paper’s reference list.
- Not checked — no full text of the sourcecites [40] Cani L, Scott SA, Joseph NS, Risk of infections in multiple myeloma patients treated with bispecific antibodies. Blood 2024; 144: 3311. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
What the sources say
- Supportedcites [8] Moreau P, Garfall AL, van de Donk N, Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022; 387: 495– 505. 35661166 PMC10587778 source
The Results > Safety passage reports cytokine release syndrome in 119 of 165 MajesTEC-1 patients receiving teclistamab (72.1%). The cited paper supplies the monotherapy comparator; the 60.1% Tec-Dara figure is the citing study’s own result, not a result attributed to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Introduction
What the sources say
- Not matchedcites [7] Garfall AL, Nooka AK, van de Donk NWCJ, Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL, USA.
We don’t have this paper’s reference list.
- Supportedcites [8] Moreau P, Garfall AL, van de Donk N, Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022; 387: 495– 505. 35661166 PMC10587778 source
The Discussion states that the phase 1–2 study found deep and durable responses to teclistamab in patients with triple-class–exposed relapsed or refractory multiple myeloma. The Methods identify the study as MajesTEC-1, and the Results report a median of five previous therapy lines and a median response duration of 18.4 months. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Tec-Dara resulted in a significantly lower risk of disease progression or death than DPd/DVd (P<0.0001); the P value crossed the prespecified stopping boundary for superiority for the first interim analysis (P=0.0139).”
- Also stated in: § Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. · boosted
“After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd.”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Results > Efficacy
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients achieving ≥CR was significantly higher with Tec-Dara versus DPd/DVd (81.8% vs. 32.1%), with a risk ratio (post-hoc) of 2.55 (95% CI, 2.14–3.03; Table 2).”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Results > Efficacy
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 67 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 26
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675 · cited 1×
“23”
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · cited 1×
“18 MRD was assessed in patients with suspected ≥CR, and at 6, 12, 18, and 24 months post-cycle 1 day 1 (±1 month) for patients with confirmed ≥CR. Serum was collected to assess teclistamab and daratumumab pharmacokinetics and immunogenicity.”
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 1×
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively), 8 with most events being grade 1 and occurring during the step-up dosing schedule.”
InfluentialSelf-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · cited 1×
“16– 18 Disease evaluations were performed centrally; imaging and bone marrow analysis for response were performed locally.”
Self-citationCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827 · cited 5×
“As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/ DVd. 5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR…”
InfluentialSelf-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationDimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344 · cited 2×
“18 MRD was assessed in patients with suspected ≥CR, and at 6, 12, 18, and 24 months post-cycle 1 day 1 (±1 month) for patients with confirmed ≥CR. Serum was collected to assess teclistamab and daratumumab pharmacokinetics and immunogenicity.”
Self-citationRaje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Cited by
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 39
Self-citationTalquetamab–Daratumumab in Relapsed or Refractory Myeloma
Mina, R., Beksac, M., Rodríguez‐Otero, P., Chen, W., Mateos, M., Li, J., Moreau, P., Cohen, Y. C., Min, C., Jelínek, T., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604657 · Cited by 28
Self-citationvan de Donk, N. W. C. J., Sonneveld, P., & Einsele, H. (2026) · Blood · doi:10.1182/blood.2025032536 · Cited by 15
Raab, M. S., Weinhold, N., Kortüm, K. M., Krönke, J., Fenk, R. R., Weisel, K. C., Podola, L., Bertsch, U., Brobeil, A., Mersi, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04471-x · Cited by 11
Self-citationGagelmann, N., Einsele, H., Flossdorf, S., Smaili, S., Metzeler, K., Scheid, C., Bullinger, L., Sauer, S., Raab, M., Duyster, J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01806-6 · Cited by 5
“…results of the MajesTEC-3 trial, which demonstrated an 83% reduction in the risk of progression or death with teclistamab plus daratumumab in a similar second-line population [34], introduce bispecific antibody-based combinations as a potentially competing strategy in the same therapeutic space.”
Self-citationDimopoulos, M. A., Schjesvold, F. H., Fu, C., Hartley-Brown, M. A., Gomez, C., Reece, D. E., Mikala, G., Alkharabsheh, O., Parrish, C., Crusoé, E. D. Q., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01088-3 · Cited by 9
Self-citationReshaping multiple myeloma treatment: recent breakthroughs
Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Yasui, H., Idogawa, M., Ishida, T., & Imai, K. (2025) · Cells · doi:10.3390/cells15010046 · Cited by 4
How I treat plasma cell leukemia
Hadidi, S. A., van Rhee, F., & Anderson, L. D. (2026) · Blood · doi:10.1182/blood.2025032145 · Cited by 4
Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 5
Does ciltacabtagene autoleucel have a future in multiple myeloma?
Mohyuddin, G. R., Cliff, E. R. S., & Chakraborty, R. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01159-6 · Cited by 2
Piron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 8
“Clinical trials evaluating teclistamab and IMiDs and/or anti-CD38 antibodies (MajesTEC-2/TRIMM-2 71 /MajesTEC-3 72 ) reported high infection rates (93% and 96.5% for all grades, 63% and 54.1% for grade ≥ 3, respectively).”
InfluentialMajesTEC-3: Redefining what’s possible in multiple myeloma
Hadidi, S. A., & Gaballa, M. (2026) · Clinical Hematology International · doi:10.46989/001c.158751 · Cited by 1
Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM
Lawrence, L. (2026) · Cancer · doi:10.1002/cncr.70299 · Cited by 1
Ntanasis‐Stathopoulos, I., Manganas, S., Filippatos, C., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70312 · Cited by 1
Self-citationFerreri, C. J., Atrash, S., Knight, M., Davis, D., McKay, J., Lambird, J. E., Homsy, S., Bernal‐Mizrachi, L., Friend, R. N., Paul, B. A., et al. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100050 · Cited by 1
CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma
Banerjee, R. K. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019898 · Cited by 1
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Banerjee, R. K., Cheung, M. C., Derman, B. A., Messersmith, H. J., Hadidi, S. A., Bhella, S., Chmielewski, C., Ebraheem, M. S., Kennedy, C. T., Kumar, S. K., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01139 · Cited by 1
Janakiram, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020073 · Cited by 1
Lim, K. J. C., Kumar, S. K., Parrondo, R. D., Chhabra, S., Tan, M. S. Y., Dooley, K. E., Corraes, A. D. M. S., Gertz, M. A., Hwa, Y. L., Stephens, H. J. B., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70425 · Cited by 1
Scheid, C., Gödel, P., Krone, C., Carpinteiro, E., Hallek, M., Holtick, U., & Richardson, T. (2026) · HemaSphere · doi:10.1002/hem3.70417 · Cited by 1
Mondal, S., Becker, N. J., Huo, Y., Zhang, P., Johnson, T. S., Landgren, O., Coffey, D. G., Walker, B. A., & Liu, E. (2026) · Biomedicines · doi:10.3390/biomedicines14071556 · Cited by 3
“A recent trial (MajesTEC-3) evaluating the combination of the bispecific antibody teclistamab with daratumumab in RRMM patients resulted in 83.4% PFS at 36 months, suggesting a promising future for applying anti-CD38-based combination therapies in treating relapsed patients [65].”
InfluentialThe future of ciltacabtagene autoleucel in multiple myeloma has just begun
Merz, M., & Gagelmann, N. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01184-5 · Cited by 1
“Despite the encouraging efficacy of teclistamab in the MajesTEC-3 trial 6 Correspondence considering bispecific T cell-engagers as the safer default option should weigh cumulative, time-on-treatment infection risk against a single exposure.”
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
Mian, H. S., & Costa, L. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2604761 · Cited by 1
Self-citationRavi, G., Dhakal, B., Callander, N. S., Medvedova, E., Dholaria, B., Godby, K. N., Bal, S., Huls, F., Silbermann, R. W., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70478 · Cited by 1
Self-citationNieto, M. J., Shih, Y.-H., Fang, J., Qiu, Y., Gentili, C., & Rivera, G. H. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2702128 · Cited by 1
Advances in multiple myeloma: key updates from the ASH 2025 meeting
Naing, P. T., & Baljević, M. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01802-w · Cited by 1
“The overall response rate (ORR) in Tec-Dara arm was striking, comparable to CAR-T therapy [3, 4], suggesting that this combination could fundamentally alter our treatment and long-term outcomes expectations.”
MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma
Killock, D. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01116-9
Biting the Tail of CAR-T for Relapsed Multiple Myeloma
Popat, R. (2026) · New England Journal of Medicine · doi:10.1056/nejme2517627
Liu, Y., Lee, J. H., Mo, C. C., Salman, T. J., Hossain, S., Midha, S., Nadeem, O., Nicholson, T., Croteau, J., Kazierad, N., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2646947 · Cited by 3
“Moreover, combination with other immune-based therapies, including the anti-BCMA bispecific antibodies teclistamab [72,73] and ABBV-383 [74], has been shown to be feasible and highly active in RRMM.”
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Self-citationIn reply: Why selinexor remains a subpar option?
Mohyuddin, G. R., & Meirson, T. (2026) · The Oncologist · doi:10.1093/oncolo/oyag113
Kennedy, C. T., & Banerjee, R. K. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261441044
Improving control arms in 2026 US myeloma trials
Ding, K., Kunesh, J., Neupane, K., & Mohyuddin, G. R. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020329 · Cited by 1
“12 13-15 These advances also have been incorporated into the National Comprehensive Cancer Network guidelines, which now list cilta-cel and daratumumab-teclistamab as the preferred category 1 regimens after 1 previous line of therapy that included lenalidomide and a proteasome inhibitor for…”
Costa, L. J., Nair, S., O’Hara, M., Slavcev, M., Gupta‐Werner, N., Doyle, M., Ammann, E. M., Patel, S., Lin, X., & Mateos, M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.009
Self-citationChanging the Treatment Landscape in Amyloid Light Chain Cardiomyopathy
Stern, L. K., & Kittleson, M. M. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.107542
Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging Solutions
Ekpenyong, E. M., Mohsin, M., Hadidi, S. A., & Yellapragada, S. V. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.010
Krejcik, J., Sponaas, A., & Mutis, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845748
CAR T-cell therapy at first relapse in myeloma
Kim, J. L., & Rajkumar, S. V. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00176-2
Chen, X., Hakim, S., Lien, Y. T., Dimopoulos, M. A., Lichtman, E. I., Min, C., Chng, W. J., Ailawadhi, S., Delimpasi, S., Hrabrick, E., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.009
Self-citationHigh-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules
Mateos, M. (2026) · New England Journal of Medicine · doi:10.1056/nejme2605404
Self-citationHansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
Self-citationLipof, J. J., Bloudek, B., Ray, A., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.014
Irfan, S., Jamil, M. A., & Abid, M. B. (2026) · British Journal of Haematology · doi:10.1111/bjh.70607
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
“The use of Bela-Vd and Bela-Pd in earlier lines of therapy may affect the subsequent ef fi cacy or feasibility of other BCMA-targeted approaches, such as CAR T-cell therapies and bsAbs, which are currently considered the most effective treatment options for patients with RRMM.”
InfluentialManagement of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma
Biltibo, E. A., Chakraborty, R., & Bishop, M. R. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517460 · Cited by 1
Camargo, C., Corona-Arias, C. A., Sandoval, Y. C. C., Ballesteros, W. G. G., Agudelo, D. S. J., & Romero, G. I. T. (2026) · Journal of Applied Hematology · doi:10.4103/joah.joah_23_26
Henaff, J.-R. L., Guennec, L. L., Schirò, P., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020556
Self-citationRichter, J. R., Efebera, Y. A., Yimer, H. A., Shukla, P., Kapetanakis, V., Purser, M. F., Boytsov, N. N., & Ballew, N. L. (2026) · American Journal of Hematology · doi:10.1002/ajh.70408
Adrados, A., Pérez‐Fernández, J., García-Vicente, R., Garrote-de-Barros, A., Martínez‐López, J., Linares, M., & Hernández‐Sánchez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805129
“%) and remarkably the CR (81.8% vs. 32.1%), respectively (158).”
InfluentialMaura, F., Firestone, R., & Usmani, S. Z. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01199-2
Practical Management of Bispecific Antibodies in Multiple Myeloma
Tan, C. R. C., Korde, N., & Mian, H. S. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00159 · Cited by 1
Ludwig, H., Terpos, E., Gay, F., van de Donk, N. W. C. J., Bernhard, S., Engelhardt, M. M., Cook, G., Schjesvold, F. H., Einsele, H., Jackson, G., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70397
Self-citationMRD in multiple myeloma: Moving from “minimal” to “measurable”
Cassano, R. C., Banerjee, R. K., Afrough, A., Portuguese, A. J., Thakur, R., Cicero, K. I., Kwok, M., Foster, L. H., Buda, G., Meletath, S. K., et al. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101413
Utilisation hors AMM du vénétoclax dans le traitement du myélome
Levêque, D. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.03.007
Advances in the Research of Bispecific Antibodies in Immunotherapy for Multiple Myeloma
利, 浩. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.53213
Pathak, S., Ahmed, R., Nagy, N., Lee, S., Bader, C. S., Regmi, S., Iliopoulou, B. P., Chen, P.-I., Gupta, B., Villar‐Prados, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.27.734105
“Anti-CD38 mAb therapy may also provide a robust target for B and T cell depletion strategies in T1D utilizing chimeric antigen receptors or bispecifics which have shown increased efficacy in other contexts 32,33 .”
Mestiri, S., Assami, L., Yoosuf, Z. S. K. M., Fernandes, Q., El-Ella, D. M. A., Elsabah, H., Merhi, M., Makni‐Maalej, K., Cherif, H., Dermime, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1822508 · Cited by 1
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma
Worth, H. A., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70519
Self-citationThe rapidly evolving BCMA landscape in multiple myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2026) · Blood · doi:10.1182/blood.2026034153
Ellayan, D. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag203
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Sra, M. S., & Kumar, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2703858
“The strongest clinical evidence for combination benefit comes from MajesTEC-3, which achieved a significant improvement in PFS with teclistamab plus daratumumab [40].”
InfluentialSolovev, M. V., Mendeleeva, L. P., Soloveva, M. V., Samoilova, O. S., Davydkin, I. L., Алексеевич, Г. Т., Kaplanov, K. D., Kaporskaya, T. S., Shelekhova, T. V., Volodicheva, E. M., et al. (2026) · Гематология и трансфузиология · doi:10.35754/0234-5730-2026-71-2-142-160
De-escalation trials in multiple myeloma: past, present and future
Mian, H. S., Costa, L. J., Mohty, M., Garfall, A. L., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01186-3
“For example, trials testing bispecific T cell-engager-based combinations, such as teclistamab–daratumumab, have shown ORRs of ~90% and MRD negativity rates of 58% 16 .”
InfluentialSelf-citationRevolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Self-citationMore options, more questions in the management of early relapsed and/or refractory multiple myeloma
Tan, C. R., & Mailankody, S. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01191-6
Puła, B., Ryżewska, W., Handziuk, A., Tyczyńska, A., & Kubicki, T. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2715442
“Daratumumab can also be combined in the refractory setting with agents such as pomalidomide or carfilzomib and—as recently shown in the MajesTEC-3 study— with novel bispecific immunotherapies, including teclistamab [52,55,56].”
Self-citationPodar, K. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01121-3
Wu, M., Lu, J., & Ge, Q. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.08.002
Self-citationAdvances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies
Mathias, F., Fersing, C., Bourgarel‐Rey, V., Gabert, J. A., & Peyron, F. (2026) · Cells · doi:10.3390/cells15161439
“In the phase III trial NCT05083169, the combination of teclistamab and subcutaneous daratumumab significantly improved PFS compared with standard daratumumab-based therapy in patients with R/R MM (Table 7) [34].”
InfluentialBrooks, C., Mader, L., Kennedy, K., Naing, P. T., Sengsayadeth, S. M., Dholaria, B., Kassim, A., Profitt, S., & Baljević, M. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00816-x
“There is increasing experience with dosing Tec/Tal every 4 weeks driven by treatment response or duration on therapy in RRMM [7, 10–12].”
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 1
Barilà, G., Grassi, A., Ruocco, V., Liberatore, C., Olivari, E., Tinelli, M., Fazio, F., Morè, S., Favero, E., Cartia, C. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70751
Self-citationMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma
Bhatt, M., Rajkumar, S. V., & Kumar, S. K. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70301
EXABS-201-MM: Bispecific Antibodies Should Be Used First for Relapsed/Refractory MM
Usmani, S. Z. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00329-0
Ang, K.-K., & Chari, A. (2026) · The Hematologist · doi:10.1182/hem.v23.5.202652
Multiples Myelom: Modernes Verständnis von Heilung geht über MRD-Negativität hinaus
Weinhold, N., Raab, M., Kortüm, M., Mai, E. K., Goldschmidt, H., Einsele, H., & Rasche, L. (2026) · Deutsches Ärzteblatt · doi:10.3238/personko.2026.09.04.01
Treatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Nadeem, O., dos Santos, D. M. C., Magidson, S., Matous, J., Medvedova, E., O’Donnell, E., Redd, R. A., Liu, Y., Midha, S., Sperling, A. S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04642-w · Cited by 3
Ahrens, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Heins, S., Teipel, R., Mitsiades, C. S., Papadopoulos, E., Ahrens, K., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.010
Self-citationAl-Momany, H. T., Kaylani, D. Z., Abuhashem, O., Nofal, A. A., Saeed, A. E., Younis, O., & Alkuttob, L. A. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101343
Teclistamab Response- and Relapse-Related Immune Correlates in the MajesTEC-1 China Cohort
Xu, H., Wang, F., Vishwamitra, D., Yang, H., Davis, C., Boominathan, R., Wu, D., Niu, Z., Song, Y., Song, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.014
Self-citationCAR-T in vivo : quand le patient devient sa propre usine de production
Vilcot, F., Brugère, C.-A., Fuentealba, J., & Houot, R. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.016
T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity
van de Donk, N. W. C. J., Smits, F., O’Neill, C., Hoekman, J., Kruyswijk, S., Baglio, S. R., Zweegman, S., & Korst, C. L. B. M. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000847
“70 Together with BCMA-directed CAR T-cell therapies and belantamab mafodotin-containing regimens, teclistamab+daratumumab represents another highly effective novel BCMA-directed early relapse option.”
Lonial, S., Dimopoulos, M. A., Γαβριατοπούλου, Μ., Kim, K., Min, C.-K., Oriol, A., Moreira, C. C. C., Quach, H., Qiu, L., Xia, Z., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00450-x · Cited by 1
Self-citationJoshi, A., Puliafito, B. R., Cirstea, D. D., Branagan, A. R., Gustine, J. N., Shome, R., Panaroni, C., Yee, A. J., & Raje, N. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000853
Ntanasis‐Stathopoulos, I., Terpos, E., & Dimopoulos, M. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000845
Self-citationTailoring Therapy for Frail and Elderly Myeloma Patients
George, T., & Szalat, R. E. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000850
Myélome multiple en 2026 : stratégies thérapeutiques en situation de rechute
Debureaux, P.-É., Cazaubiel, T., Chalopin, T., & Talbot, A. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.008
CD3-engaging bispecific antibodies convert human regulatory T cells into cytotoxic effectorsPreprint
Michel, J. J., Frenking, J. H., Metzler, A., Schach, A., Meermeier, E. W., Thiel, V., Kehl, N., Wagner, T. R., Zoller, J., Cuntz, S., et al. (2026) · medRxiv · doi:10.64898/2026.09.23.26363285
Younis, O. M., Göklemez, S., Awadallah, C., Atrash, S., Paul, B. A., Shaikh, H. G., Strouse, C. S., Vegel, A. J., Struble, E., Mazloom, A., et al. (2026) · Cancers · doi:10.3390/cancers18193147
Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma
Nishimura, Y., Gaur, G., Cottini, F., & Zanwar, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1956522
Matsumura, N. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03211-y
O’Neill, C. A., Broekmans, M. E. C., Korst, C. L. B. M., Krevvata, M., Collo, G. D., Groen, R. W. J., Li, B., Baglio, S. R., Philippar, U., Pillarisetti, K., et al. (2026) · HemaSphere · doi:10.1002/hem3.70487 · Cited by 1
Merz, M., Filho, J. T. S., Voorhees, P. M., Einsele, H., Schjesvold, F., Cliff, E. R. S., Mateos, M.-V., Hungria, V., Cohen, Y. C., de Larrea, C. F., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01850-2
“2A): CARTITUDE-4 (cilta-cel) [23, 24], MajesTEC-3 (teclistamab-daratumumab) [25], Monu-menTAL-3 (talquetamab-daratumumab with or without pomalidomide) [26], and APOLLO (DPd, providing the”
Self-citationMartino, M. V., Bilardi, E., Pitea, M., Porto, G., Policastro, G., Utano, G., Giordano, L., Santoro, G., Germanò, J., & Alati, C. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70328
Metadata
- Authors
- Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., Kim, K., Min, C. K., Geerts, P., Van Leeuwen-Segarceanu, E., Tyczynska, A., Reguera, J. L., Johansson, M., Hansson, M., Turgut, M., Grey, M., Sidana, S., Rodriguez-Otero, P., Martinez-Lopez, J., Hashmi, H., Carson, R., Kobos, R., Sun, W., Lantz, K., Seifert, A., Briseno-Toomey, D., O’Rourke, L., Rubin, M., Vieyra, D., Kang, L., & Mateos, M. V.
- Affiliations
- University of Alabama at Birmingham (US)
- University of Calgary (CA)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Winship Cancer Institute (US)
- Peking University People's Hospital (CN)
- Royal Marsden NHS Foundation Trust (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina
- Hôpital de Jolimont (BE)
- Clinica São Germano, São Paulo
- Princess Margaret Cancer Centre (CA)
- Sichuan University (CN)
- Rigshospitalet (DK)
- Odense University Hospital (DK)
- University Hospital Carl Gustav Carus (DE)
- University of Tübingen (DE)
- Korea University (KR)
- Istituto di Ematologia di Bologna (IT)
- Hyogo Medical University Hospital (JP)
- Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Isala (NL)
- St. Antonius Ziekenhuis (NL)
- Department of Hematology and Transplantology, Medical University of Gdansk; Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland
- Instituto de Biomedicina de Sevilla (ES)
- Sunderby sjukhus (SE)
- Sahlgrenska University Hospital (SE)
- Ondokuz Mayıs University (TR)
- Blackpool Victoria Hospital (GB)
- Stanford Medicine (US)
- Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
- Hematology Department, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, Centro de Investigación Biomédica en Red de Cáncer, Madrid
- Memorial Sloan Kettering Cancer Center (US)
- Johnson & Johnson (United States) (US)
- Johnson & Johnson (United Kingdom) (GB)
- Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain
- ORCID
- Costa, Luciano J.
- Bahlis, Nizar J.
- Perrot, Aurore
- Nooka, Ajay K.
- Lu, Jin
- Pawlyn, Charlotte
- Mina, Roberto
- Kentos, Alain
- Reece, Donna
- Niu, Ting
- Teipel, Raphael
- Dimopoulos, Meletios A.
- Zamagni, Elena
- Yoshihara, Satoshi
- Min, Chang Ki
- Geerts, Paul
- Reguera, Juan Luis
- Hansson, Markus
- Turgut, Mehmet
- Sidana, Surbhi
- Hashmi, Hamza
- Kang, Lijuan
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-02-19
- Volume
- 394
- Issue
- 8
- Pages
- 739-752
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC13218738
- OpenAlex
- W4417156840
- Cited by
- 119
- References
- 35
- Citations by year
- 2026: 117
- FWCI
- 81.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Johnson & Johnson
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- teclistamab, daratumumab, relapsed/refractory multiple myeloma, bispecific antibodies, CD38, progression-free survival, dexamethasone, pomalidomide, bortezomib, combination therapy, adverse events
- MeSH terms
- Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Thalidomide, Time Factors, Antibodies, Bispecific, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.